TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Charles River CEO Defends WuXi PharmaTech Purchase ChinaBio Today submits: Charles River Laboratories (NYSE: CRL) defended its $1.6 billion purchase of much-smaller WuXi PharmaTech (NYSE: WX) Monday, even though the transaction will bring only incremental profit growth in the near term. According to CEO James C. Foster, WuXi gives Charles River a major foothold in China, a significant market for CRO services. Plus, the purchase takes Charles River into a new business sector: early-stage drug discovery. Foster’s comments were carried in a Boston Globe article that gave background to the purchase in Charles River’s home base of Boston (see story).Complete Story » seekingalpha.com |
Lice Are Peskier Than Ever Some common treatments for killing head lice may no longer be effective because some of the pests have built up a resistance to them. online.wsj.com |
MannKind / Seaside 88: Not Good News for Investors Derek Lowe submits: Readers may remember Generex (GNBT), the company that's developing a buccal insulin spray. I'm not sold on their technology or their prospects, to put it mildly. In this post I took a look at the investment outfit that did a stock transaction with the company, and found them not to my taste, either.Complete Story » seekingalpha.com |
Novartis Prices New M.S. Drug Novartis said its new drug for multiple sclerosis will have a wholesale price of about $48,000 a year per person in the U.S., making it among the most expensive drugs for the disease. online.wsj.com |
PPD and Bend Research Enter into Collaboration to Offer Comprehensive Formulation Development and Analytical Testing Capabilities [Business Wire] - PPD, Inc. and Bend Research, Inc. today announced they have entered into a collaboration in the areas of formulation development, analytical testing and clinical supplies manufacturing to provide pharmaceutical and biotechnology companies a full range of chemistry, manufacturing and controls development services. us.rd.yahoo.com |